Expression of the Apoptotic Proteins in Glioblastoma U87-MG Cell Line Treated by Botulinum Toxin
International Clinical Neuroscience Journal,
Vol. 7 No. 3 (2020),
21 June 2020
Background: Glioblastoma multiforme (GBM) is the most type of brain malignancy in adults. Radical excision surgery, chemotherapy, and radiotherapy in some cases are still unsuccessful, and most patients with GBM die within three to six months following diagnosis. Botulinum toxin type A (BtxA) has cellular toxin effects and suppresses the cell division of certain types of cancer cell lines in vivo and in vitro study. The present study designed to evaluate the apoptotic effect of BtxA on the GBM cell line.
Material & methods: U87-MG GBM cell line cultured according to the routing protocols, divided into two groups including, trial (BtxA treated) and control groups. Cells of the trial group exposed to different doses of BtxA. The cell viability, cycle arrest, and pro-apoptotic proteins evaluated respectively by MTT assay, SubG1, and Western blotting.
Results: MTT assay showed that the viability of the BtxA treated cells at doses of 1.45 Unit and other doses after 24 to 48 hours, significantly decreased (p<0.001) compared to the control groups. Apoptosis percentage of the SubG1 test also indicated that 1.45 Unit dose significantly increased in the cells exposed to BtxA compared to the control group in 24 hours. The expression of P53 and Caspase 3 proteins indicated a significant increase.
Conclusion: BtxA induces apoptosis in U87- MG cell line via p53 and caspase three pathways and could have clinical applications. In vivo studies need to confirm the clinical application of the present findings.
- Glioblastoma multiforme
- U87-MG cell line
- Botulinum toxin type A
- Caspase 3
How to Cite
Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770.
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine. 2008;5(1):e8.
Blachon S, Demeret C. The regulatory E2 proteins of human genital papillomaviruses are pro-apoptotic. Biochimie. 2003;85(8):813-9.
Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU international. 2005;96(6):848-52.
Darwish HA, Arab HH, Abdelsalam RM. Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib. Toxicology and applied pharmacology. 2014;279(2):129-40.
Radwan MM, Ramdan K, Abu-Azab I, Abu-Zidan FM, Fikri A. Botulinum toxin treatment for anal fissure. African health sciences. 2007;7(1).
Abramovitz A, Goyeneche C, Cánchica A, Burgues T, Sucupira E. Botulinum toxin application in the facial muscles for the treatment of stuttering. Journal of Laryngology and Voice. 2017;7(1):14.
Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, et al. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. The Prostate. 2009;69(11):1143-50.
Bandala C, Perez-Santos JLM, Lara-Padilla E, Delgado L, Anaya-Ruiz M. Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pacific Journal of Cancer Prevention. 2013;14(2):891-4.
Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nature Reviews Cancer. 2014;14(5):359.
Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, et al. Cancer statistics for African Americans. CA: a cancer journal for clinicians. 2002;52(6):326-41.
Galanis E, Buckner J. Chemotherapy for high-grade gliomas. British journal of cancer. 2000;82(8):1371.
Zhang Y, Dube C, Gibert M, Cruickshanks N, Wang B, Coughlan M, et al. The p53 pathway in glioblastoma. Cancers. 2018;10(9):297.
Hu G, Wei B, Wang L, Wang L, Kong D, Jin Y, et al. Analysis of gene expression profiles associated with glioma progression. Molecular medicine reports. 2015;12(2):1884-90.
De Groot M, Aronica E, Heimans J, Reijneveld J. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology. 2011;77(6):532-9.
Jin Y, Xiao W, Song T, Feng G, Dai Z. Expression and prognostic significance of p53 in glioma patients: a meta-analysis. Neurochemical research. 2016;41(7):1723-31.
Tirapelli LF, Bolini PHNA, Tirapelli DPdC, Peria FM, Becker ANP, Saggioro FP, et al. Caspase-3 and Bcl-2 expression in glioblastoma: an immunohistochemical study. Arquivos de neuro-psiquiatria. 2010;68(4):603-7.
- Abstract Viewed: 271 times
- PDF Downloaded: 290 times